Exosomes carrying immune checkpoints, a promising therapeutic approach in cancer treatment.
Cancer progression
Exosomal immune checkpoint
Exosome
Immune checkpoint
Tumor-derived exosomes
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
07 Sep 2022
07 Sep 2022
Historique:
received:
08
06
2022
accepted:
20
06
2022
entrez:
7
9
2022
pubmed:
8
9
2022
medline:
11
9
2022
Statut:
epublish
Résumé
Exosomes are a subgroup of extracellular vesicles generated by distinct cells. Tumor-derived extracellular vesicles convey immunological checkpoint molecules. TEXs as critical mediators in tumor development, metastasis, and immune escape have recently become the focus of scientific research. Exosomes are involved in the regulation of the immune system. Exosomes interact with target cells in the tumor microenvironment, changing their function based on the cargo they contain. Exosomal immune checkpoints might be exploited to track tumor immune evasion, treatment response, and patient prognosis while enhancing tumor cell proliferation and spread. This review focuses on tumor-derived exosomes, their immunosuppressive effects in mice models, and their role in cancer immunotherapy. Exosomes are being studied as possible cancer vaccines, with numerous uses in tumor immunotherapy. Exosomes can carry chemotherapeutics, siRNA, and monoclonal antibodies. Exosomes produced by macrophages might be used to treat cancer. These and other clinical consequences provide new doors for cancer treatment.
Identifiants
pubmed: 36071295
doi: 10.1007/s12032-022-01781-1
pii: 10.1007/s12032-022-01781-1
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
183Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Dai J, Su Y, Zhong S, Cong L, Liu B, Yang J, et al. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct Target Ther. 2020;5(1):145. https://doi.org/10.1038/s41392-020-00261-0 .
doi: 10.1038/s41392-020-00261-0
pubmed: 32759948
pmcid: 7406508
Johnstone RM, Adam M, Hammond J, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 1987;262(19):9412–20.
pubmed: 3597417
doi: 10.1016/S0021-9258(18)48095-7
Bahrami A, Moradi Binabaj MA, Ferns G. Exosomes: emerging modulators of signal transduction in colorectal cancer from molecular understanding to clinical application. Biomed Pharmacother. 2021;141:111882. https://doi.org/10.1016/j.biopha.2021.111882 .
doi: 10.1016/j.biopha.2021.111882
pubmed: 34218003
Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
pubmed: 32029601
pmcid: 7717626
doi: 10.1126/science.aau6977
Sun W, Ren Y, Lu Z, Zhao X. The potential roles of exosomes in pancreatic cancer initiation and metastasis. Mol Cancer. 2020;19(1):1–18.
doi: 10.1186/s12943-020-01255-w
Ahmadi M, Rezaie J. Tumor cells derived-exosomes as angiogenenic agents: possible therapeutic implications. J Transl Med. 2020;18(1):1–17.
doi: 10.1186/s12967-020-02426-5
Gluszko A, Mirza SM, Piszczatowska K, Kantor I, Struga M, Szczepanski MJ. The role of tumor-derived exosomes in tumor angiogenesis and tumor progression. Curr Issues Pharm Med Sci. 2019;32(4):193–202.
doi: 10.2478/cipms-2019-0034
Pan X, Zheng L. Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment. Cell Mol Immunol. 2020;17(9):940–53.
pubmed: 32699350
pmcid: 7609272
doi: 10.1038/s41423-020-0505-9
Olejarz W, Dominiak A, Żołnierzak A, Kubiak-Tomaszewska G, Lorenc T. Tumor-derived exosomes in immunosuppression and immunotherapy. J Immunol Res. 2020;2020:6272498. https://doi.org/10.1155/2020/6272498 .
Xing C, Li H, Li R-J, Yin L, Zhang H-F, Huang Z-N, et al. The roles of exosomal immune checkpoint proteins in tumors. Mil Med Res. 2021;8(1):1–10.
Lawler SE, Nowicki MO, Ricklefs FL, Chiocca EA. Immune escape mediated by exosomal PD-L1 in cancer. Adv Biosyst. 2020;4(12):2000017.
doi: 10.1002/adbi.202000017
Shimizu A, Sawada K, Kobayashi M, Yamamoto M, Yagi T, Kinose Y, et al. Exosomal CD47 plays an essential role in immune evasion in ovarian cancer. Mol Cancer Res. 2021;19(9):1583–95.
pubmed: 34016744
doi: 10.1158/1541-7786.MCR-20-0956
You L, Wu W, Wang X, Fang L, Adam V, Nepovimova E, et al. The role of hypoxia-inducible factor 1 in tumor immune evasion. Med Res Rev. 2021;41(3):1622–43.
pubmed: 33305856
doi: 10.1002/med.21771
Spugnini EP, Logozzi M, Di Raimo R, Mizzoni D, Fais S. A role of tumor-released exosomes in paracrine dissemination and metastasis. Int J Mol Sci. 2018;19(12):3968.
pmcid: 6321583
doi: 10.3390/ijms19123968
Fu S, Wang Y, Xia X, Zheng JC. Exosome engineering: current progress in cargo loading and targeted delivery. NanoImpact. 2020;20:100261. https://doi.org/10.1016/j.impact.2020.100261 .
doi: 10.1016/j.impact.2020.100261
Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, et al. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Can Res. 2005;65(12):5238–47.
doi: 10.1158/0008-5472.CAN-04-3804
Taghikhani A, Farzaneh F, Sharifzad F, Mardpour S, Ebrahimi M, Hassan ZM. Engineered tumor-derived extracellular vesicles: potentials in cancer immunotherapy. Front Immunol. 2020. https://doi.org/10.3389/fimmu.2020.00221 .
doi: 10.3389/fimmu.2020.00221
pubmed: 32210954
pmcid: 7069476
Yen E-Y, Miaw S-C, Yu J-S, Lai IR. Exosomal TGF-β1 is correlated with lymphatic metastasis of gastric cancers. Am J Cancer Res. 2017;7(11):2199–208.
pubmed: 29218244
pmcid: 5714749
Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S, et al. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ. 2008;15(1):80–8.
pubmed: 17932500
doi: 10.1038/sj.cdd.4402237
Hao Q, Wu Y, Wu Y, Wang P, Vadgama JV. Tumor-derived exosomes in tumor-induced immune suppression. Int J Mol Sci. 2022;23(3):1461.
pubmed: 35163380
pmcid: 8836190
doi: 10.3390/ijms23031461
Lundholm M, Schröder M, Nagaeva O, Baranov V, Widmark A, Mincheva-Nilsson L, et al. Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS ONE. 2014;9(9):e108925.
pubmed: 25268476
pmcid: 4182531
doi: 10.1371/journal.pone.0108925
Mittelbrunn M, Gutiérrez-Vázquez C, Villarroya-Beltri C, González S, Sánchez-Cabo F, González MÁ, et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun. 2011;2(1):1–10.
doi: 10.1038/ncomms1285
Shojaei S, Hashemi SM, Ghanbarian H, Salehi M, Mohammadi-Yeganeh S. Effect of mesenchymal stem cells-derived exosomes on tumor microenvironment: tumor progression versus tumor suppression. J Cell Physiol. 2019;234(4):3394–409.
pubmed: 30362503
doi: 10.1002/jcp.27326
Shen Y, Xue C, Li X, Ba L, Gu J, Sun Z, et al. Effects of gastric cancer cell-derived exosomes on the immune regulation of mesenchymal stem cells by the NF-kB signaling pathway. Stem Cells Dev. 2019;28(7):464–76.
pubmed: 30717632
doi: 10.1089/scd.2018.0125
Mulero MC, Huxford T, Ghosh G. NF-κB, IκB, and IKK: integral components of immune system signaling. Struct Immunol. 2019. https://doi.org/10.1007/978-981-13-9367-9_10 .
doi: 10.1007/978-981-13-9367-9_10
Mishra V, Pathak C. Human Toll-Like Receptor 4 (hTLR4): Structural and functional dynamics in cancer. Int J Biol Macromol. 2019;122:425–51.
pubmed: 30365988
doi: 10.1016/j.ijbiomac.2018.10.142
Domenis R, Cifù A, Marinò D, Fabris M, Niazi KR, Soon-Shiong P, et al. Toll-Like receptor-4 activation boosts the immunosuppressive properties of tumor cells-derived exosomes. Sci Rep. 2019;9(1):1–14.
doi: 10.1038/s41598-019-44949-y
Mirzaei R, Sarkar S, Dzikowski L, Rawji KS, Khan L, Faissner A, et al. Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity. Oxfordshire: Taylor & Francis; 2018. p. e1478647.
Bland CL, Byrne-Hoffman CN, Fernandez A, Rellick SL, Deng W, Klinke DJ. Exosomes derived from B16F0 melanoma cells alter the transcriptome of cytotoxic T cells that impacts mitochondrial respiration. FEBS J. 2018;285(6):1033–50.
pubmed: 29399967
pmcid: 6457271
doi: 10.1111/febs.14396
Wu Y, Deng W, McGinley EC, Klinke DJ. Melanoma exosomes deliver a complex biological payload that upregulates PTPN 11 to suppress T lymphocyte function. Pigment Cell Melanoma Res. 2017;30(2):203–18.
pubmed: 27930879
pmcid: 5360477
doi: 10.1111/pcmr.12564
Tung SL, Boardman DA, Sen M, Letizia M, Peng Q, Cianci N, et al. Regulatory T cell-derived extracellular vesicles modify dendritic cell function. Sci Rep. 2018;8(1):1–12.
doi: 10.1038/s41598-018-24531-8
Li L, Cao B, Liang X, Lu S, Luo H, Wang Z, et al. Microenvironmental oxygen pressure orchestrates an anti-and pro-tumoral γδ T cell equilibrium via tumor-derived exosomes. Oncogene. 2019;38(15):2830–43.
pubmed: 30546089
doi: 10.1038/s41388-018-0627-z
Muntasell A, Berger AC, Roche PA. T cell-induced secretion of MHC class II–peptide complexes on B cell exosomes. EMBO J. 2007;26(19):4263–72.
pubmed: 17805347
pmcid: 2230838
doi: 10.1038/sj.emboj.7601842
Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8(3):239–45.
pubmed: 17304234
doi: 10.1038/ni1443
Lotfinejad P, Kazemi T, Mokhtarzadeh A, Shanehbandi D, Niaragh FJ, Safaei S, et al. PD-1/PD-L1 axis importance and tumor microenvironment immune cells. Life Sci. 2020;259:118297.
pubmed: 32822718
doi: 10.1016/j.lfs.2020.118297
Tang Y, Zhang P, Wang Y, Wang J, Su M, Wang Y, et al. The biogenesis, biology, and clinical significance of exosomal PD-L1 in cancer. Front Immunol. 2020;11:604.
pubmed: 32322256
pmcid: 7158891
doi: 10.3389/fimmu.2020.00604
Fan Y, Che X, Qu J, Hou K, Wen T, Li Z, et al. Exosomal PD-L1 retains immunosuppressive activity and is associated with gastric cancer prognosis. Ann Surg Oncol. 2019;26(11):3745–55.
pubmed: 31087180
doi: 10.1245/s10434-019-07431-7
Liang B, Hu X, Ding Y, Liu M. Tumor-derived exosomes in the PD-1/PD-L1 axis: Significant regulators as well as promising clinical targets. J Cell Physiol. 2021;236(6):4138–51.
pubmed: 33275291
doi: 10.1002/jcp.30197
Zhou K, Guo S, Li F, Sun Q, Liang G. Exosomal PD-L1: new insights into tumor immune escape mechanisms and therapeutic strategies. Front Cell Dev Biol. 2020. https://doi.org/10.3389/fcell.2020.569219 .
doi: 10.3389/fcell.2020.569219
pubmed: 33987175
pmcid: 7779769
Ye L, Zhu Z, Chen X, Zhang H, Huang J, Gu S, et al. The Importance of exosomal PD-L1 in cancer progression and its potential as a therapeutic target. Cells. 2021;10(11):3247.
pubmed: 34831468
pmcid: 8619537
doi: 10.3390/cells10113247
Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560(7718):382–6.
pubmed: 30089911
pmcid: 6095740
doi: 10.1038/s41586-018-0392-8
Yang Y, Li C-W, Chan L-C, Wei Y, Hsu J-M, Xia W, et al. Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res. 2018;28(8):862–4.
pubmed: 29959401
pmcid: 6082826
doi: 10.1038/s41422-018-0060-4
Kim DH, Kim H, Choi YJ, Kim SY, Lee J-E, Sung KJ, et al. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer. Exp Mol Med. 2019;51(8):1–13.
pubmed: 31827074
pmcid: 6881327
Cordonnier M, Nardin C, Chanteloup G, Derangere V, Algros M-P, Arnould L, et al. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients. J Extracell Vesicles. 2020;9(1):1710899.
pubmed: 32002173
pmcid: 6968537
doi: 10.1080/20013078.2019.1710899
Zhang C, Fan Y, Che X, Zhang M, Li Z, Li C, et al. Anti-PD-1 therapy response predicted by the combination of exosomal PD-L1 and CD28. Front Oncol. 2020;10:760.
pubmed: 32528882
pmcid: 7266952
doi: 10.3389/fonc.2020.00760
Qiu Y, Yang Y, Yang R, Liu C, Hsu J-M, Jiang Z, et al. Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer. Oncogene. 2021;40(31):4992–5001.
pubmed: 34172932
pmcid: 8342306
doi: 10.1038/s41388-021-01896-1
Poggio M, Hu T, Pai C-C, Chu B, Belair CD, Chang A, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177(2):414-27. e13.
pubmed: 30951669
pmcid: 6499401
doi: 10.1016/j.cell.2019.02.016
Li X, Liu Y, Yang L, Jiang Y, Qian Q. TIM-3 shuttled by MV3 cells-secreted exosomes inhibits CD4+ T cell immune function and induces macrophage M2 polarization to promote the growth and metastasis of melanoma cells. Transl Oncol. 2022;18:101334. https://doi.org/10.1016/j.tranon.2021.101334 .
doi: 10.1016/j.tranon.2021.101334
pubmed: 35093790
pmcid: 8808081
Chatterjee S, Chatterjee A, Jana S, Dey S, Roy H, Das MK, et al. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer. Carcinogenesis. 2021;42(1):38–47.
pubmed: 32832992
doi: 10.1093/carcin/bgaa092
Shenoy GN, Bhatta M, Bankert RB. Tumor-associated exosomes: a potential therapeutic target for restoring anti-tumor T Cell responses in human tumor microenvironments. Cells. 2021;10(11):3155. https://doi.org/10.3390/cells10113155 .
doi: 10.3390/cells10113155
pubmed: 34831378
pmcid: 8619102
Miyazaki T, Ikeda K, Sato W, Horie-Inoue K, Inoue S. Extracellular vesicle-mediated EBAG9 transfer from cancer cells to tumor microenvironment promotes immune escape and tumor progression. Oncogenesis. 2018;7(1):7. https://doi.org/10.1038/s41389-017-0022-6 .
doi: 10.1038/s41389-017-0022-6
pubmed: 29362448
pmcid: 5833691
Gao J, Qiu X, Li X, Fan H, Zhang F, Lv T, et al. Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer. Biochem Biophys Res Commun. 2018;498(3):409–15. https://doi.org/10.1016/j.bbrc.2018.02.114 .
doi: 10.1016/j.bbrc.2018.02.114
pubmed: 29452091
Wang Y, Li P, Mao S, Mo Z, Cao Z, Luo J, et al. Exosome CTLA-4 regulates PTEN/CD44 signal pathway in spleen deficiency internal environment to promote invasion and metastasis of hepatocellular carcinoma. Front Pharmacol. 2021;12:757194-. https://doi.org/10.3389/fphar.2021.757194 .
doi: 10.3389/fphar.2021.757194
pubmed: 34744733
pmcid: 8564353
Li X, Liu Y, Zheng S, Zhang T, Wu J, Sun Y, et al. Role of exosomes in the immune microenvironment of ovarian cancer. Oncol Lett. 2021;21(5):1–17.
pubmed: 33240407
doi: 10.3892/ol.2021.12638
Kelleher RJ Jr, Balu-Iyer S, Loyall J, Sacca AJ, Shenoy GN, Peng P, et al. Extracellular vesicles present in human ovarian tumor microenvironments induce a phosphatidylserine-dependent arrest in the T-cell signaling cascade. Cancer Immunol Res. 2015;3(11):1269–78. https://doi.org/10.1158/2326-6066.cir-15-0086 .
doi: 10.1158/2326-6066.cir-15-0086
pubmed: 26112921
pmcid: 4636911
Shenoy GN, Loyall J, Maguire O, Iyer V, Kelleher RJ Jr, Minderman H, et al. Exosomes associated with human ovarian tumors harbor a reversible checkpoint of T-cell responses. Cancer Immunol Res. 2018;6(2):236–47. https://doi.org/10.1158/2326-6066.cir-17-0113 .
doi: 10.1158/2326-6066.cir-17-0113
pubmed: 29301753
pmcid: 5845437
Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014;14(3):195–208.
pubmed: 24566916
pmcid: 4350779
doi: 10.1038/nri3622
Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, Ohyashiki JH. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood, J Am Soc Hematol. 2014;124(25):3748–57.
Ye SB, Zhang H, Cai TT, Liu YN, Ni JJ, He J, et al. Exosomal miR-24-3p impedes T-cell function by targeting FGF11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma. J Pathol. 2016;240(3):329–40.
pubmed: 27538493
doi: 10.1002/path.4781
Czystowska-Kuzmicz M, Sosnowska A, Nowis D, Ramji K, Szajnik M, Chlebowska-Tuz J, et al. Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat Commun. 2019;10(1):3000. https://doi.org/10.1038/s41467-019-10979-3 .
doi: 10.1038/s41467-019-10979-3
pubmed: 31278254
pmcid: 6611910
Jafarzadeh N, Gholampour MA, Alivand M-R, Kavousi S, Arzi L, Rad F, et al. CML derived exosomes promote tumor favorable functional performance in T cells. BMC Cancer. 2021;21(1):1002. https://doi.org/10.1186/s12885-021-08734-3 .
doi: 10.1186/s12885-021-08734-3
pubmed: 34493241
pmcid: 8424959
Clayton A, Mitchell JP, Court J, Mason MD, Tabi Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res. 2007;67(15):7458–66. https://doi.org/10.1158/0008-5472.can-06-3456 .
doi: 10.1158/0008-5472.can-06-3456
pubmed: 17671216
Theodoraki M-N, Yerneni S, Gooding WE, Ohr J, Clump DA, Bauman JE, et al. Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT. Oncoimmunology. 2019;8(7):e1593805.
doi: 10.1080/2162402X.2019.1593805
Zhu L, Kalimuthu S, Gangadaran P, Oh JM, Lee HW, Baek SH, et al. Exosomes derived from natural killer cells exert therapeutic effect in melanoma. Theranostics. 2017;7(10):2732.
pubmed: 28819459
pmcid: 5558565
doi: 10.7150/thno.18752
Shoae-Hassani A, Hamidieh AA, Behfar M, Mohseni R, Mortazavi-Tabatabaei SA, Asgharzadeh S. NK cell–derived exosomes from NK Cells previously exposed to neuroblastoma cells augment the antitumor activity of cytokine-activated NK cells. J Immunother (Hagerstown, Md: 1997). 2017;40(7):265.
Azambuja JH, Ludwig N, Yerneni S, Rao A, Braganhol E, Whiteside TL. Molecular profiles and immunomodulatory activities of glioblastoma-derived exosomes. Neuro Oncol Adv. 2020;2(1):vdaa056.
doi: 10.1093/noajnl/vdaa056
Mao Y, Wang Y, Dong L, Zhang Q, Wang C, Zhang Y, et al. Circulating exosomes from esophageal squamous cell carcinoma mediate the generation of B10 and PD-1high Breg cells. Cancer Sci. 2019;110(9):2700–10.
pubmed: 31276257
pmcid: 6726703
doi: 10.1111/cas.14122
Seo Y, Kim H-S, Hong I-S. Stem cell-derived extracellular vesicles as immunomodulatory therapeutics. Stem cells int. 2019. https://doi.org/10.1155/2019/5126156 .
doi: 10.1155/2019/5126156
pubmed: 31467565
pmcid: 6701316
Czystowska-Kuzmicz M, Sosnowska A, Nowis D, Ramji K, Szajnik M, Chlebowska-Tuz J, et al. Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat Commun. 2019;10(1):1–16.
doi: 10.1038/s41467-019-10979-3
Razzo BM, Ludwig N, Hong C-S, Sharma P, Fabian KP, Fecek RJ, et al. Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. Carcinogenesis. 2020;41(5):625–33.
pubmed: 31245809
doi: 10.1093/carcin/bgz124
Ning Y, Shen K, Wu Q, Sun X, Bai Y, Xie Y, et al. Tumor exosomes block dendritic cells maturation to decrease the T cell immune response. Immunol Lett. 2018;199:36–43.
pubmed: 29800589
doi: 10.1016/j.imlet.2018.05.002
Chen J, Song Y, Miao F, Chen G, Zhu Y, Wu N, et al. PDL1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8+ T cell exhaustion during metastasis. Cancer Sci. 2021;112(9):3437.
pubmed: 34152672
pmcid: 8409314
doi: 10.1111/cas.15033
Wen J, Chang X, Bai B, Gao Q, Zhao Y. Orexin A suppresses the expression of exosomal PD-L1 in colon cancer and promotes T cell activity by inhibiting JAK2/STAT3 signaling pathway. Dig Dis Sci. 2022;67(6):2173–2181. https://doi.org/10.1007/s10620-021-07077-0 .
Sun Y, Guo J, Yu L, Guo T, Wang J, Wang X, et al. PD-L1+ exosomes from bone marrow-derived cells of tumor-bearing mice inhibit antitumor immunity. Cell Mol Immunol. 2021;18(10):2402–9.
pubmed: 32606317
doi: 10.1038/s41423-020-0487-7
Zeng L, Liao Z, Li W, Yuan Q, Wu P, Gu Z, et al. Non-covalent glycosylated gold nanoparticles/peptides nanovaccine as potential cancer vaccines. Chin Chem Lett. 2020;31(5):1162–4.
doi: 10.1016/j.cclet.2019.10.015
Gu X, Erb U, Büchler MW, Zöller M. Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice. Int J Cancer. 2015;136(4):E74–84.
pubmed: 25066479
doi: 10.1002/ijc.29100
Shin K, Kim J, Park J, Kim OR, Kang N, Kim I-H. Prognostic significance of exosomal programmed death-ligand 1 in advanced gastric cancer patients treated with first-line chemotherapy. American Society of Clinical Oncology; 2022.
Shimada Y, Matsubayashi J, Kudo Y, Maehara S, Takeuchi S, Hagiwara M, et al. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer. Sci Rep. 2021;11(1):1–10.
doi: 10.1038/s41598-021-87575-3
Cheng Z, Wang L, Wu C, Huang L, Ruan Y, Xue W. Tumor-derived exosomes induced M2 macrophage polarization and promoted the metastasis of osteosarcoma cells through Tim-3. Arch Med Res. 2021;52(2):200–10.
pubmed: 33162186
doi: 10.1016/j.arcmed.2020.10.018
Ren W, Zhang X, Li W, Feng Q, Feng H, Tong Y, et al. Exosomal miRNA-107 induces myeloid-derived suppressor cell expansion in gastric cancer. Cancer Manag Res. 2019;11:4023.
pubmed: 31190980
pmcid: 6511657
doi: 10.2147/CMAR.S198886
Narita M, Kanda T, Abe T, Uchiyama T, Iwafuchi M, Zheng Z, et al. Immune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine. Int J Oncol. 2015;46(4):1699–709.
pubmed: 25625346
doi: 10.3892/ijo.2015.2846
Cheng L, Wang Y, Huang L. Exosomes from M1-polarized macrophages potentiate the cancer vaccine by creating a pro-inflammatory microenvironment in the lymph node. Mol Ther. 2017;25(7):1665–75.
pubmed: 28284981
pmcid: 5498801
doi: 10.1016/j.ymthe.2017.02.007
Zhang L, Yu D. Exosomes in cancer development, metastasis, and immunity. Biochim Biophys Acta. 2019;1871(2):455–68.
Andaloussi SE, Lakhal S, Mäger I, Wood MJ. Exosomes for targeted siRNA delivery across biological barriers. Adv Drug Deliv Rev. 2013;65(3):391–7.
pubmed: 22921840
doi: 10.1016/j.addr.2012.08.008
Zhang F, Guo J, Zhang Z, Qian Y, Wang G, Duan M, et al. Mesenchymal stem cell-derived exosome: a tumor regulator and carrier for targeted tumor therapy. Cancer Lett. 2022;526:29–40.
pubmed: 34800567
doi: 10.1016/j.canlet.2021.11.015
Bagheri E, Abnous K, Farzad SA, Taghdisi SM, Ramezani M, Alibolandi M. Targeted doxorubicin-loaded mesenchymal stem cells-derived exosomes as a versatile platform for fighting against colorectal cancer. Life Sci. 2020;261:118369.
pubmed: 32882265
doi: 10.1016/j.lfs.2020.118369
Liu J, Ye Z, Xiang M, Chang B, Cui J, Ji T, et al. Functional extracellular vesicles engineered with lipid-grafted hyaluronic acid effectively reverse cancer drug resistance. Biomaterials. 2019;223:119475.
pubmed: 31520888
doi: 10.1016/j.biomaterials.2019.119475
Zhao Y, Liu L, Sun R, Cui G, Guo S, Han S, et al. Exosomes in cancer immunoediting and immunotherapy. Asian J Pharm Sci. 2022. https://doi.org/10.1016/j.ajps.2021.12.001 .
doi: 10.1016/j.ajps.2021.12.001
pubmed: 36105313
pmcid: 9237629
Zhou W, Zhou Y, Chen X, Ning T, Chen H, Guo Q, et al. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2021;268:120546. https://doi.org/10.1016/j.biomaterials.2020.120546 .
pubmed: 33253966
doi: 10.1016/j.biomaterials.2020.120546
Xu HY, Li N, Yao N, Xu XF, Wang HX, Liu XY, et al. CD8+ T cells stimulated by exosomes derived from RenCa cells mediate specific immune responses through the FasL/Fas signaling pathway and combined with GM-CSF and IL-12, enhance the anti-renal cortical adenocarcinoma effect. Oncol Rep. 2019;42(2):866–79.
pubmed: 31233203
Lu Z, Zuo B, Jing R, Gao X, Rao Q, Liu Z, et al. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. J Hepatol. 2017;67(4):739–48.
pubmed: 28549917
doi: 10.1016/j.jhep.2017.05.019
Näslund TI, Gehrmann U, Qazi KR, Karlsson MC, Gabrielsson S. Dendritic cell–derived exosomes need to activate both T and B cells to induce antitumor immunity. J Immunol. 2013;190(6):2712–9.
pubmed: 23418627
doi: 10.4049/jimmunol.1203082
Sticht C, De La Torre C, Parveen A, Gretz N. miRWalk: an online resource for prediction of microRNA binding sites. PLoS ONE. 2018;13(10):e0206239.
pubmed: 30335862
pmcid: 6193719
doi: 10.1371/journal.pone.0206239
Xu N, He D, Shao Y, Qu Y, Ye K, Memet O, et al. Lung-derived exosomes in phosgene-induced acute lung injury regulate the functions of mesenchymal stem cells partially via miR-28-5p. Biomed Pharmacother. 2020;121:109603.
pubmed: 31707339
doi: 10.1016/j.biopha.2019.109603
Hou X, Wan W, Wang J, Li M, Wang Y, Yao Y, et al. Let-7a inhibits migration of melanoma cells via down-regulation of HMGA2 expression. Am J Transl Res. 2016;8(9):3656.
pubmed: 27725848
pmcid: 5040666
Liu J, Han Y, Hu S, Cai Y, Yang J, Ren S, et al. Circulating exosomal MiR-107 restrains tumorigenesis in diffuse large B-Cell lymphoma by targeting 14-3-3η. Front Cell Dev Biol. 2021;9:845.
Wang S, Li L, Hu X, Liu T, Jiang W, Wu R, et al. Effects of atrial fibrillation-derived exosome delivery of miR-107 to human umbilical vein endothelial cells. DNA Cell Biol. 2021;40(4):568–79.
pubmed: 33651959
doi: 10.1089/dna.2020.6356
Ni Q, Stevic I, Pan C, Müller V, Oliveira-Ferrer L, Pantel K, et al. Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients. Sci Rep. 2018;8(1):1–10.
doi: 10.1038/s41598-018-31108-y
Zhu L, Chen Y, Chen M, Wang W. Mechanism of miR-204–5p in exosomes derived from bronchoalveolar lavage fluid on the progression of pulmonary fibrosis via AP1S2. AnnTransl Med. 2021. https://doi.org/10.21037/atm-20-8033 .
doi: 10.21037/atm-20-8033
pubmed: 35590215
Yao S, Yin Y, Jin G, Li D, Li M, Hu Y, et al. Exosome-mediated delivery of miR-204-5p inhibits tumor growth and chemoresistance. Cancer Med. 2020;9(16):5989–98.
pubmed: 32618144
pmcid: 7433811
doi: 10.1002/cam4.3248